Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 20/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 20/20 | 0.54 |
| ▸ | PARP1 | P09874 | 19/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL16704152 | 1.00 | TNKS (0.54) | TNKSTNKS2PARP1 | |
| SCHEMBL16701424 | 0.89 | TNKS (0.61) | TNKSTNKS2PARP1 | |
| SCHEMBL16701410 | 0.80 | TNKS (0.59) | TNKSTNKS2PARP1 | |
| SCHEMBL18058753 | 0.78 | TNKS (0.65) | TNKSTNKS2PARP1 | |
| SCHEMBL16711597 | 0.75 | TNKS (0.53) | TNKSTNKS2PARP1 | |
| SCHEMBL18746194 | 0.74 | TNKS (0.37) | TNKSTNKS2PARP1 | |
| Potassium Ion SCHEMBL16701622 | 0.72 | TNKS (0.64) | TNKSTNKS2PARP1 | |
| SCHEMBL20954737 | 0.71 | TNKS (1.00) | TNKSTNKS2PARP1 | |
| SCHEMBL16711554 | 0.70 | TNKS (1.00) | TNKSTNKS2PARP1 | |
| SCHEMBL16711634 | 0.70 | TNKS (0.79) | TNKSTNKS2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066099-B1 | PYRIDO[2,3-D]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | LILLY CO ELI (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9624218-B2 | Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors | ELI LILLY AND COMPANY (US) | 2017-04-18 | — | — | US | disclosed |
| EP-3066099-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | Eli Lilly and Company (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160251348-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | ELI LILLY AND COMPANY | 2016-09-01 | — | — | US | disclosed |
| WO-2015069512-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251348-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | TNKS, TYMP, TNKS1BP1 | TNKS 1/4885TNKS2 7/4885PARP1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.